LY3841136

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

ObesityKidney DiseaseLiver

190 competitors in Obesity

#DrugCompanyPhaseTrials

1

Retatrutide

Eli Lilly

Phase 3

62

Synthroid

IInstitut Jerome Lejeune

Phase 3

13

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

14

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

45

Mibavademab

Regeneron

Phase 3

26

Elecoglipron

AstraZeneca

Phase 3

17

PF-08653944

Pfizer

Phase 3

58

Survodutide

Boehringer Ingelheim

Phase 3

29

Aleniglipron

GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Phase 3

210

LY3841136

Eli Lilly

Phase 2

3Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Overweight3 trials

A Study of LY3841136 in Japanese Participants With Obesity or Overweight

Completed·Eli Lilly·Phase 1·NCT06297616·128 enrolled

A Study of LY3841136 in Overweight and Obese Participants

Completed·Eli Lilly·Phase 1·NCT06345066·96 enrolled

A Study of LY3841136 in Healthy and Overweight Participants

Completed·Eli Lilly·Phase 1·NCT05295940·148 enrolled

Obesity3 trials

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or Overweight

Recruiting·Eli Lilly·Phase 2·NCT06143956·1,481 enrolled

A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Active, not recruiting·Eli Lilly·Phase 2·NCT06603571·367 enrolled

A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Completed·Eli Lilly·Phase 2·NCT06230523·263 enrolled

Liver1 trial

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

Recruiting·Eli Lilly·Phase 1·NCT07401862·36 enrolled

Kidney Disease1 trial

A Phase 1, Multicenter, Parallel-Design, Single Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Eloralintide in Participants With Severe Renal Impairment and End Stage Renal Disease (ESRD) Compared With Participants With Normal Renal Function

Active, not recruiting·Eli Lilly·Phase 1·NCT07426380·28 enrolled

Details

Drug Info

Related News